Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
Prnewswire·2026-01-26 13:30
LAS VEGAS, Jan. 26, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced its participation in the 15th European Pancreas and Islet Transplantation Association (EPITA) Symposium, held January 25-27, 2026, in Igls, Austria. As a leader in immunosuppression-free cell therapy solutions, Avant is actively evaluating advanced cells for potential ap ...